By Kris B. Mamula, Pittsburgh Business Times


Cancer diagnostics company Cernostics announced Tuesday it had received two patents in the United States and a third patent in Japan.


The patents pertain to different aspects of the Uptown Pittsburgh company’s TissueCypher™ technology platform.


“These patents are an important part of our intellectual property strategy and provide our technology platform with long term market exclusivity,” CEO Mike Hoerres said in a prepared statement. “No other diagnostics technology can replicate our tissue systems biology approach to anatomic pathology – the TissueCypher™ playform will bring unique, actionable information to the health care community.”


Cernostics is collaborating with health care organizations worldwide to bring the product to market, including Geisinger Health System, University of Pittsburgh and University of Pennsylvania.